期刊文献+

小鼠代谢性高尿酸血症模型的复制方法初探 被引量:33

A Preliminary Study on the Establishment of a Mouse Model of Hyperuricemia
下载PDF
导出
摘要 目的本实验分别单独使用或联合使用次黄嘌呤、尿酸氧化酶抑制剂复制小鼠代谢性高尿酸血症模型,观察造模后受试动物血清尿酸值的变化,以确定次黄嘌呤、尿酸氧化酶抑制剂造模的最佳方式、给药途径和剂量,并通过阳性药验证该模型的可行性。方法采用次黄嘌呤灌胃或腹腔注射给药,尿酸氧化酶抑制剂腹腔或皮下注射给药,分别测定造模后不同时段小鼠血尿酸值。结果复制小鼠高尿酸血症模型,采用腹腔注射次黄嘌呤500 mg/kg,皮下注射尿酸氧化酶抑制剂50 mg/kg,1、35、h后,血尿酸值明显高于正常组(P<0.01),且阳性药可显著降低升高的尿酸值(P<0.01)。结论腹腔注射次黄嘌呤500 mg/kg和皮下注射尿酸氧化酶抑制剂50 mg/kg配合使用,是复制小鼠高尿酸血症模型的适当组合。 Objective To investigate the effects of hypoxanthine and uricase inhibitor used singly or. in combination on the concentration of serum uric acid in mice, to determine the optimal procedure, route and dosage of drug administration, and to evaluate the feasibility of this method to establish a mouse model of hyperuricemia. Methods After i.g. or i. p administration of hypoxanthine and i.p. or s.c. injection of uricasc inhibitor, the concentration of serum uric acld was measured at different time intervals. Results At 1, 3, 5 hours after i.p. injection of hypoxanthine in a dose of 500 mg/kg and s.c. injection of uricasc inhibitor in a dose of 50 mg/kg, the level of serum uric acid in mice was significantly increased (P 〈 0.01 ). Moreover, positively reacting drug, s can significantly reduce the increased serum uric acid in those mice (P 〈 0.01 ). Conclusion Intrapcritoneal injection of hypoxanthine in a dose of 500 mg/kg and subcutaneous injection of uricase inhibitor in a dose of 50 mg/kg, administered in an appropriate combination, is a reliable method to induce significant increase of serum uric acid in mice and can be used as a suitable method to establish a mouse model of hyperuricemia.
作者 徐立 时乐
出处 《中国比较医学杂志》 CAS 2006年第1期1-4,共4页 Chinese Journal of Comparative Medicine
基金 2005年度省属高校自然科学研究计划一般项目(批准号:05KJB310097)
关键词 高尿酸血症 次黄嘌呤 尿酸氧化酶抑制剂 模型 动物 Hyperuricemia Hypoxanthine Uricase inhibitor Model, Animal Mouse
  • 相关文献

参考文献5

二级参考文献44

  • 1董纯武,顾耀志,吴祖立,姚龙涛,王秀贤,徐永根,蔡玉书.鸡痛风病研究报告[J].中国兽医杂志,1989,15(2):24-27. 被引量:7
  • 2杨岫岩,唐福林.21家医院痛风住院构成比15年变化趋势分析[J].中华流行病学杂志,1996,17(1):10-12. 被引量:67
  • 3孟昭享.痛风[M].北京:北京医科大学,中国医科大学联合出版社,1997.. 被引量:7
  • 4陈新谦 金有豫.新编药物学(第14 版)[M].北京:人民卫生出版社,1997.. 被引量:1
  • 5康格非.临床生化化学[M].北京:人民卫生出版社,1995.. 被引量:1
  • 6[1]Star VL, Hochberg M. Prevention and management of gout. Drug,1993, 45:212-222. 被引量:1
  • 7[2]Wortmann RL, Management of hyperuricemia. In: McCarthy DJ, Koopman WJ, Arthritis and allied conditions 12th ed., Philadelphia, Lea and Febiger, 1993. 1807-1818. 被引量:1
  • 8[3]Campion EW, Glynn RJ,DeLabry LO. A symptomatic hyper-uricemia: risks and consequences in the normative again study [J]. Am J Med,1987,82:421-424. 被引量:1
  • 9[4]Li Y, Stamler J, Xiao Z, et al. Serum uric acid and its correlates in Chinese adult populations, urban and rural, of Beijing: the PRC-USA collaborative study in cardiovascular and cardiopulmonary epidemiology. Int J Epidemiol,1997,26:288-296. 被引量:1
  • 10[5]Kelley WN. Antihyperuricemic drugs. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, Textbook of Rheumatology, Philadelphia, WB Saunders, 1991,862-877. 被引量:1

共引文献147

同被引文献286

引证文献33

二级引证文献302

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部